Cytovance Biologics has been awarded a manufacturing contract to continue development of BiologicMD’s osteoporosis drug, PTH-CBD. The agreement will lead to the development of the manufacturing platform that will allow BiologicsMD to conduct Phase I studies.   “We are excited to announce our partnership with Cytovance to develop the manufacturing platform for our PTH-CBD treatment. Their expertise will play a key role in accelerating the development of this compound that will hopefully improve t...